Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gum treatment may ease heart failure burden

NCT ID NCT07036289

Disease control Sponsor: University of Taubate Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether deep cleaning for gum disease can lower a key heart failure marker in the blood. About 80 adults with or without heart failure will receive dental scaling and root planing. Researchers will track changes in NT-proBNP levels and gum health over 6 months to see if treating periodontitis helps manage heart failure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
mechanical dental treatment (scaling and root planing)
What this could lead to
If it works, this could show that treating gum disease helps control heart failure, offering a simple add-on to standard care.
What could go wrong
This is a small, early-stage study with only 80 participants. It may not prove a clear benefit, and results might not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Jun 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * minimum of 35 years of age; * possibility and availability for medical and dental examinations; * specifically for HF groups: HF having as primary causes ischemic problems, myocardial infarction, hypertension and valvulopathies will be selected * HF with intermediate or reduced ejection fraction under one of the three following pharmacological therapeutic regimens: a) Angiotensin Converting Enzyme Inhibitors, as the first option, or b) Angiotensin II Receptor Blockers and b) Angiotensin II Receptor Blockers and c) Angiotensin/neprilysin receptor inhibitors. Exclusion Criteria: * pregnant or lactating women; * individuals with stage D of HF using vasoactive drugs or circulatory devices; * HF individuals with preserved ejection fraction; * participants who do not meet the criteria for periodontal disease; * participants who are unable to comply with the study protocol; * diabetes, obesity, chronic kidney disease and other non-ischemic causes of HF; * familial and congenital heart alterations and myocarditis * rheumatological and autoimmune diseases; * drugs and cardiotoxic substances such as cocaine and oncological chemotherapy; * Specifically for the negative control group a progression of periodontitis revealed by 0.3mm additional clinical attachment loss within 6 months of follow-up.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Periodontitis

Contacts and locations

Locations

  • University of Taubate Dental School

    Taubaté, São Paulo, 12020-330, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.